The US pharmaceutical market represents the single greatest commercial opportunity for life sciences companies worldwide, but it’s also one of the most challenging to navigate successfully.
A fragmented payer landscape, evolving policy frameworks, and diverse stakeholder incentives create significant hurdles for even the most promising therapies. From the Inflation Reduction Act to PBM transparency requirements and Most Favoured Nation Pricing, the rules of engagement are shifting rapidly and global teams need to understand these dynamics to build effective pricing and access strategies.
That’s why we’re excited to share that two of our senior experts, Nick Proctor and Louisa Oliver Byrne, are running a comprehensive one-day course on Understanding Pharma Market Access in the US with CELforPharma on 22nd October.
Why This Course Matters
This session offers a practical, in-depth look at how US market access operates, tailored for global and cross-functional professionals who need to understand its complexities. Whether you’re in Medical Affairs, Marketing, Clinical Development, Health Outcomes, or transitioning from an in-country role to a global position, this course provides the essential foundation you need.
Nick brings over 25 years of pricing and reimbursement expertise, including extensive on-the-ground experience working with US payers and supporting major product launches. Louisa leads our US Managed Care Centre of Excellence and specialises in access strategy, value story development, and evidence generation tailored to US stakeholders. Together, they’ve authored resources including Market Access in the IRP Era, and Louisa has explored critical policy topics like MFN pricing in depth through our podcast series.
They’ll guide you through the key players, systems, and decision-making processes that determine market access outcomes and equip you with practical frameworks to navigate them effectively.
What Participants Are Saying
“This is one of the best Market Access trainings I have taken. The course materials were excellent, concise, and very well-structured… The pace of the course and the balance with questions and answers were perfect!”
—
Oramon Nimkannon, Capability Lead Pricing & Contracting
Boehringer Ingelheim
“I can highly recommend this course! Nick and Louisa gave a very clear presentation of the US Market Access systems.”
—
Florian Toussaint, Market Access and Public Affairs Manager
GSK
Ready to Master US Market Access?
Don’t miss this opportunity to learn from two of our subject matter experts in an interactive, discussion-rich format.
Register now for the CELforPharma US Pharma Market Access course and gain the insights you need to drive success in the world’s most important pharmaceutical market.
Dive Deeper Into US Policy Changes
Want to understand the implications of Most Favoured Nation pricing before the course? Louisa recently explored this complex topic in our podcast Beyond the Headlines: Understanding MFN’s True Impact on Market Access, breaking down what these policy shifts really mean for pricing and access strategies.
And if you’re navigating the intersection of US pricing decisions and international reference pricing, our resource Market Access in the IRP Era provides essential insights into managing global pricing strategies in an increasingly interconnected landscape.
